Thursday, 5 November 2026European Markets

ALMUNDA PRO NV And NEURONES Have A High Dividend Yield And Return On Equity In The Technology Sector.

Loading stream...

(vianews) - almunda pro nv (amund.as) is among this list of stock assets with the highest dividend rate and return on equity on the technology sector.

financial asset price forward dividend yield return on equity
almunda pro nv (amund.as) €1.13 5.22% 6.32%
neurones (nro.pa) €45.80 2.61% 14.87%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. almunda pro nv (amund.as)

5.22% forward dividend yield and 6.32% return on equity

almunda professionals n.v. provides digital transformation, data management, regulatory change, and consultancy services in the netherlands and internationally. the company was formerly known as novisource n.v. and changed its name to almunda professionals n.v. in august 2021. almunda professionals n.v. was founded in 2001 and is headquartered in amsterdam, the netherlands.

earnings per share

as for profitability, almunda pro nv has a trailing twelve months eps of €0.02.

pe ratio

almunda pro nv has a trailing twelve months price to earnings ratio of 56.5. meaning, the purchaser of the share is investing €56.5 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.32%.

volume

today's last reported volume for almunda pro nv is 78 which is 95.06% below its average volume of 1581.

revenue growth

year-on-year quarterly revenue growth grew by 20.3%, now sitting on 30.01m for the twelve trailing months.

yearly top and bottom value

almunda pro nv's stock is valued at €1.13 at 02:30 est, way under its 52-week high of €1.34 and higher than its 52-week low of €1.08.

more news about almunda pro nv.

2. neurones (nro.pa)

2.61% forward dividend yield and 14.87% return on equity

neurones s.a., an information technology (it) services company, provides infrastructure, application, and consulting services in france and internationally. its infrastructure services include infrastructure management, manages public and private cloud services, it operations, user support, devops, cybersecurity, it service management, information system governance, and automation. the company also provides application services in the areas of sap, digital, web, mobility, ux/ui, enterprise content and document management, business process management, robotic process automation, dematerialization, it consulting for finance, big data, and devops, it training and change management, and innovation connected devices (iot). in addition, it offers consulting services, including management and digital transformation, and digital marketing consulting; digital transformation services in the areas of agile/scrum, devops, ci/cd, cloud, infrastructure as code, cyber security, analytics, big data, mobility, digital workplace, connected devices, innovations, client experience, ux/ui, and digital marketing, as well as internal process digitization, ecm/bpm, rpa, dematerialization, ai, predictive maintenance, machine learning, and blockchain; and managed services/outsourcing services. the company serves banking/insurance, services/consumer goods, energy/utilities/healthcare, technologies/media/telecoms, industry/public works and civil engineering, and public sector markets. neurones s.a. was founded in 1984 and is based in nanterre, france.

earnings per share

as for profitability, neurones has a trailing twelve months eps of €1.96.

pe ratio

neurones has a trailing twelve months price to earnings ratio of 23.37. meaning, the purchaser of the share is investing €23.37 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 14.87%.

volume

today's last reported volume for neurones is 2114 which is 75.38% below its average volume of 8587.

more news about neurones.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com